New Drug Licensing to Bear Fruit in Q4: AP Biosciences, Oneness Biotech, and TAHO Pharmaceuticals Gain International Attention

Taiwan’s new drug licensing momentum is accelerating, with several companies expected to see results next quarter. The biotech sector has recently attracted significant capital inflows, with companies such as OBI Pharma’s AP Biosciences, MICROBIO Group’s Oneness Biotech, and TAHO Pharmaceuticals gaining attention as their pipeline products move closer to licensing milestones, with positive developments anticipated in the coming quarter.